CTLA4 and head and neck squamous cell carcinoma: Nonetheless, clinical outcomes have been variable; for instance, the phase III EAGLE trial (NCT02369874) in R/M HNSCC revealed no statistically significant improvement in OS with durvalumab (anti-PD-L1) plus tremelimumab (anti-CTLA-4) compared to durvalumab monotherapy[93].